Erasca, Inc. announced two clinical trial collaboration and supply agreements (CTCSAs) with Novartis for the MEK inhibitor trametinib (MEKINIST®). The agreements will support the clinical development of the pan-RAF inhibitor naporafenib in combination with trametinib for the treatment of patients with RAS Q61X solid tumors in the Phase 1b SEACRAFT-1 trial and in patients with previously treated NRAS-mutant (NRASm) unresectable or metastatic melanoma in the randomized, pivotal Phase 3 SEACRAFT-2 trial. Erasca is sponsoring the trials, and Novartis is supplying trametinib at no cost.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.09 USD | +3.98% | +11.17% | -1.88% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.88% | 304M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- ERAS Stock
- News Erasca, Inc.
- Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials